Search Results - "Chirovsky, Diana"

Network meta-analysis of pembrolizumab as monotherapy and in combination with chemotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.

Alternate Title: Metanálise em rede comparativa de pembrolizumabe como monoterapia e em combinação com quimioterapia para tratamento de primeira linha de carcinoma de células escamosas da cabeça e pescoço recorrente ou metastático.

Authors: Mojebi, Ali Ramakrishnan, Karthik Ayers, Dieter et al.

Source: JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde. abr2024, Vol. 16 Issue 1, p25-64. 40p.

Subjects: SQUAMOUS cell carcinoma, COMBINATION drug therapy, PEMBROLIZUMAB, BAYESIAN analysis, OVERALL survival

Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.

Authors: Lala, Mallika Chirovsky, Diana Cheng, Jonathan D. et al.

Source: Oral Oncology. Sep2018, Vol. 84, p108-120. 13p.

Attainment of Goal and Normalized Lipid Levels With Lipid-Modifying Therapy in Malaysia.

Authors: Tun-Ying Hsu Chirovsky, Diana Foong Ming Moy et al.

Source: Clinical Therapeutics. 2013, Vol. 35 Issue 4, p450-460. 11p.

The Effects of Isolated versus Multiple Lipid Disorders on Resource Utilization among Metabolic Syndrome Patients with Lipid Abnormalities despite Lipid-Modifying Treatment.

Authors: Ambegaonkar, Baishali Chirovsky, Diana Wu, Wenchen et al.

Source: Cardiology. Nov2010, Vol. 117 Issue 2, p96-104. 9p. 5 Charts.

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.

Authors: Grünwald, Viktor Chirovsky, Diana Cheung, Winson Y. et al.

Source: Oral Oncology. Mar2020, Vol. 102, pN.PAG-N.PAG. 1p.

First-line treatment patterns and outcomes in advanced non-small cell lung cancer in Sweden: a population-based real-world study with focus on immunotherapy.

Authors: Wagenius, Gunnar Vikström, Anders Berglund, Anders et al.

Source: Acta Oncologica. 2024, Vol. 63 Issue 1, p198-205. 8p.

Screening for hepatocellular carcinoma in chronic liver disease.

Authors: Chirovsky, Diana Hassmiller Lich, Kristen Barritt IV, A. Sidney et al.

Source: Annals of Internal Medicine. 2/3/2015, Vol. 162 Issue 3, p238-239. 2p.

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.

Authors: Hughes, Brett G. M. Mendoza, Rene Gonzalez Basset-Seguin, Nicole et al.

Source: Dermatology & Therapy. Oct2021, Vol. 11 Issue 5, p1777-1790. 14p.

Attainment of normal lipid levels among high cardiovascular risk patients: Pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.

Authors: Ambegaonkar, Baishali M. Bash, Lori D. Chirovsky, Diana R. et al.

Source: European Journal of Internal Medicine. Oct2013, Vol. 24 Issue 7, p656-663. 8p.

Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.

Authors: Hirji, Ishan Gupta, Shaloo Goren, Amir et al.

Source: Health & Quality of Life Outcomes. 2013, Vol. 11 Issue 1, p1-11. 11p. 2 Diagrams, 3 Charts.

Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.

Authors: Harrington, Kevin J Soulières, Denis Tourneau, Christophe Le et al.

Source: JNCI: Journal of the National Cancer Institute. Feb2021, Vol. 113 Issue 2, p171-181. 11p.

RWD95 Healthcare Cost and Resource Utilization among First Line (1L) Treated Patients with Metastatic Non-small Cell Lung Cancer (mNSCLC): Analysis of SEER-Medicare Linked Claims in the US.

Authors: Babel, Riddhi Wehler, Elizabeth Syed, Safiuddin Shoeb et al.

Source: Value in Health. 2025 Supplement 1, Vol. 28 Issue 6, pS380-S380. 1p.

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Authors: Rischin, Danny Harrington, Kevin J. Greil, Richard et al.

Source: Oral Oncology. May2022, Vol. 128, pN.PAG-N.PAG. 1p.

5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.

Authors: Velcheti V Rai P Kao YH et al.

Source: Clinical lung cancer [Clin Lung Cancer] 2024 Sep; Vol. 25 (6), pp. 502-508.e3. Date of Electronic Publication: 2024 May 16.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection.

Authors: Hu X Chirovsky D Walker MS et al.

Source: BMC pulmonary medicine [BMC Pulm Med] 2024 Jul 10; Vol. 24 (1), pp. 332. Date of Electronic Publication: 2024 Jul 10.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2466 (Electronic) Linking ISSN: 14712466 NLM ISO Abbreviation: BMC Pulm Med Subsets: MEDLINE

Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer.

Authors: Donington J Hu X Zhang S et al.

Source: Clinical lung cancer [Clin Lung Cancer] 2024 Jul; Vol. 25 (5), pp. 440-448. Date of Electronic Publication: 2024 Mar 22.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.

Authors: Liu SV Babel RA Kao YH et al.

Source: Immunotherapy [Immunotherapy] 2025 Oct; Vol. 17 (14), pp. 1005-1013. Date of Electronic Publication: 2025 Oct 17.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE

Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study.

Authors: Herbst RS Cho BC Zhou C et al.

Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2025 Sep; Vol. 20 (9), pp. 1302-1314. Date of Electronic Publication: 2025 May 24.

Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE

Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors.

Authors: Halmos B Rai P Min J et al.

Source: Frontiers in oncology [Front Oncol] 2024 Apr 18; Vol. 14, pp. 1285280. Date of Electronic Publication: 2024 Apr 18 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data.

Authors: West H Hu X Zhang S et al.

Source: Clinical lung cancer [Clin Lung Cancer] 2023 May; Vol. 24 (3), pp. 260-268. Date of Electronic Publication: 2022 Dec 25.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE